GlassScriptPhysician profile
James S Dolgin
NPI 1679655864
$422.37
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $39.51 · 2021: $13.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.29 | 2019 | |
| Lupin INC. | $55.75 | 2019-2020 | |
| Millicent US INC | $38.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $29.21 | 2019 | |
| Therapeuticsmd, INC. | $28.38 | 2019-2020 | |
| Minerva Surgical, INC | $26.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.41 | 2019-2020 | |
| Allergan, INC. | $17.16 | 2019 | |
| Covidien LP | $16.70 | 2019 | |
| Mission Pharmacal Company | $13.91 | 2019 | |
| Celularity INC. | $12.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dolgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.